GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year - Seite 2

The growing rate of patient and clinical adoption and increasing sales can be attributed to several key factors:

• Patients are increasingly understanding the benefits of genetic screening, its ability to predict certain cancers before symptoms arise, allowing for earlier interventions, personalised medicine, introduction of preventative measures, family planning and potentially better outcomes. Overall genetic testing offers patients peace of mind and empowers them to take better control of their health.

• Doctors are becoming increasingly aware of clinically backed genetic screening technologies that provide detailed information on patients’ risk of developing cancer and other conditions. Even more importantly, clinicians are becoming increasingly confident with using these technologies and offering them to patients - providing early disease detection, actionable results, and the ability to offer patients personalised and superior care.
  

GENE is positioning as a leader in the field, through:

• Comprehensive Support: GENE's dedicated team of experts provides comprehensive support to clinicians, offering training, education, and ongoing assistance to ensure seamless integration of the geneType test into their practice.
  
• Evidence-Based Solutions: GENE is committed to delivering evidence-based solutions that have been rigorously validated through extensive research and clinical studies, instilling confidence in clinicians and patients alike.
  
• Global Reach: GENE's widespread presence across the USA and Australia ensures that clinicians from diverse geographic regions have access to the geneType test, democratizing personalized healthcare and improving patient outcomes on a global scale. Importantly GENE is well advanced in launching geneType in several other important geographical markets.
  

“Our success in expanding clinician adoption and growth in sales reflects the growing recognition of the transformative potential of personalized medicine,” remarked Simon Morriss, CEO of GENE. “By harnessing the power of geneType, we are empowering clinicians to deliver targeted interventions that improve patient outcomes and drive the future of healthcare forward.”

With the geneType test gaining momentum among across the USA and Australia, GENE remains steadfast in its mission to revolutionize healthcare through its constant pursuit in excellence in innovation.

For more information about GENE and the GeneType test, visit http://www.genetype.com